GLAXO.NSE News

Mumbai: GlaxoSmithKline Pharmaceuticals Limited (GSK Pharma ) has received a tax demand of Rs 23.21 crore from the Income Tax Department following a scrutiny assessment for the Assessment Year 2023-24.

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received a tax demand … portal and was received physically. GlaxoSmithKline Pharmaceuticals Limited stated that the tax demand …

New Delhi: GlaxoSmithKline Pharmaceuticals Limited has received … and documentation requirements. GlaxoSmithKline (GSK) Pharmaceuticals Limited clarified in its … appropriate action as necessary. GlaxoSmithKline Pharmaceuticals Limited, the Indian subsidiary …

Mumbai: Global biopharma major GlaxoSmithKline Pharmaceuticals, best known in India for its blockbuster legacy brands Augmentin and Calpol, is charting a bold comeback in the country. The London-headquartered company, which has completed over a century in India's pharma market, is plotting its most ambitious transformation in decades as it targets doubling its India revenue to ₹8,000 crore within 4-5 years, India MD Bhushan Akshikar told ET in an exclusive interview.This will be driven by a strategic pivot from its ₹4,000-crore base of legacy portfolio of general medicines-including medications in anti-infective, pain management, respiratory and vaccines-into specialty drugs in high-growth areas of oncology and liver diseases as well as nascent areas such as adult vaccination."Reinvention and impact are the two words that define our journey in India. Taking cue from our past but remaining completely focused on the future is how I see the next decade for us," said Akshikar. "Our base business will continue to grow while on top of that we are launching in areas where we can make a sizeable impact," he added.The bet will be on innovation-led growth, accelerated clinical trials in India, and concurrent launches of global assets to double size by the end of the decade.

GlaxoSmithKline Pharmaceuticals (GSK Pharma ) will procure 4.95 MWp … , Syngene International, a Bengaluru-based pharmaceutical company, announced procuring renewable energy … February 2025, Mumbai-based Aarti Drugs partnered with Prozeal Green Energy …

GlaxoSmithKline Pharmaceuticals (GSK) has announced it will source power from a 4.95 MW solar project of Clean Max Galapagos, a special purpose vehicle (SPV) of CleanMax, in Maharashtra.

From banking to beverages, Nirmal Bang’s Diwali portfolio highlights eight stocks poised for durable growth.

… materials, particularly active pharmaceutical ingredients (APIs) … , Executive Vice President, GlaxoSmithKline Pharmaceuticals ; Ajay Bagga, Managing … – Operations, Mankind Pharma ; Sreenivas Rao Nandigam, … Forecasting Failures in Pharma , Medical Device …

GlaxoSmithKline Pharmaceuticals is re-entering India's oncology market with the launch of Jemperli and Zejula, precision therapies for gynaecological cancers. This move marks a strategic pivot for GSK, aiming to establish a significant oncology presence in India. The company will import these therapies, focusing on access and affordability through tiered pricing and patient assistance programs.